Belimumab (Anti-TNFSF13B / BAFF / CD257)

製品コードA2316 別名: LymphoStat B 純度：99%

Belimumab (Anti-TNFSF13B / BAFF / CD257) is a human IgG1λ monoclonal antibody that inhibits B-cell activating factor (BAFF). Belimumab can be used for systemic lupus erythematosus (SLE) research. MW : 144.56 kDa.

サイズ（液体）	価格(税別)	在庫状況
1mg	JPY 44500	国内在庫なし(納期7~10日)
1mg*5	JPY 146500	お問い合わせ
1mg*25	JPY 445500	お問い合わせ

代表番号: 045-509-1970\|電子メール：sales@selleck.co.jp よく尋ねられる質問

質量管理及び製品安全説明書

現在のバッチを見る：純度： 99% タンパク質濃度： 10.159mg/ml 内毒素：＜1EU/mg

CD markers阻害剤の選択性比較

生物活性

製品説明	Belimumab (Anti-TNFSF13B / BAFF / CD257) is a human IgG1λ monoclonal antibody that inhibits B-cell activating factor (BAFF). Belimumab can be used for systemic lupus erythematosus (SLE) research. MW : 144.56 kDa.

製品説明

CAS No.	356547-88-1
Molecular Weight	144.56 kDa
Formulation	100 mM Pro-Ac, 20mM Arg, pH5.0
Isotype	Human IgG1
Source	CHO
Storage (From the date of receipt)	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.
Shipping	Shipped under low temperature conditions
Purification	AKTA
Sterility	0.2 μM filtered

各種クローンの論文数比較

^*Selleckは、市場の主要なクローンを収集し、2024年9月までの文献での使用状況を調査しました。その結果、Selleckの選定クローンが最も広く使用されていることが示されました。

臨床試験

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06191887	RECRUITING	Drug: Bendamustine\|Drug: Cyclophosphamide\|Drug: Fludarabine	B-Cell Non-Hodgkin Lymphoma; Recurrent Chronic Lymphocytic Leukemia; Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Small Lymphocytic Lymphoma; Recurrent Transformed Chronic Lymphocytic Leukemia; Refractory Chronic Lymphocytic Leukemia; Refractory Diffuse Large B-Cell Lymphoma; Refractory Follicular Lymphoma; Refractory Mantle Cell Lymphoma; Refractory Marginal Zone Lymphoma; Refractory Small Lymphocytic Lymphoma; Refractory Transformed Chronic Lymphocytic Leukemia	Mayo Clinic	2024-03-18	PHASE1
NCT07771361	NOT_YET_RECRUITING		Non-Hodgkin Lymphoma Refractory/ Relapsed; Multiple Myeloma Refractory; Multiple Myeloma in Relapse; Non-Hodgkin Lymphoma, B-cell; Non-Hodgkin Lymphoma; Non-Hodgkin Lymphoma (NHL); Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma; Multiple Myeloma in Remission	Luminary Therapeutics	2026-12	PHASE2
NCT07729995	NOT_YET_RECRUITING		Rheumatoid Arthritis (RA); Systemic Lupus Erthematosus (SLE); Dermatomyositis (DM); Systemic Sclerosis (SSc)	Luminary Therapeutics	2026-10	PHASE1
NCT06716606	RECRUITING	Drug: Belimumab	Connective Tissue Diseases	GlaxoSmithKline	2024-12-12	PHASE3
NCT07259070	RECRUITING	Drug: BAFF-R CAR-T	DLBCL; CLL; FL; MCL; WM; MZL	Institute of Hematology & Blood Diseases Hospital, China	2025-11-29	PHASE1; PHASE2
NCT05878717	RECRUITING		Systemic Sclerosis Associated Interstitial Lung Disease; Scleroderma, Systemic	GlaxoSmithKline	2023-09-13	PHASE2; PHASE3

(data from https://clinicaltrials.gov, updated on 2026-02-13)

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須